Ranbaxy stocks up as USFDA opposes Mylan?s request

in-principle allowed Ranbaxy to sell a generic version of the medicine from end of 2011, after original drugmaker Pfizer's patent expires in November. Shares of Ranbaxy Laboratories were at Rs 468, up 1.41 per cent on the NSE. It touched a high of Rs...